Quantcast

Latest Adalimumab Stories

2009-09-22 02:00:00

MAIDENHEAD, England, September 22 /PRNewswire/ -- - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and achievements of people living with rheumatoid arthritis (RA). To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/wyeth/40154/...

2009-09-08 10:33:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Autoimmune Disease Therapeutics http://www.reportlinker.com/p0131243/Autoimmune-Disease-Therapeutics.html This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Billion by the following therapeutic class - Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease (Biologics only), and Others. The report provides separate...

2009-08-06 08:00:00

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018 for Rigel Pharmaceuticals' investigational novel oral agent, fostamatinib disodium (R788). The report update is based on Rigel Pharmaceuticals' recent announcement regarding additional Phase II clinical data...

2009-08-06 07:00:00

NASHVILLE, Tenn. and GLEN ROCK, N.J., Aug. 6 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that 76 percent of surveyed pharmacy directors say that by 2014 they expect their managed care organization will have only one preferred biologic for all immune conditions, such as rheumatoid arthritis, psoriasis, Crohn's disease and ulcerative colitis. According to the new Formulary Forum report entitled Formulary Advantages in Immune Biologics: Tightening Payer Control Offers...

e160ded9130c86800bef5604e107b59e
2009-08-05 14:21:38

A group of best-selling drugs used to treat arthritis and other inflammatory diseases have been found to increase the risk of cancer in children and adolescents, prompting federal regulators on Tuesday to add stronger warning labels to the medications, The Associated Press reported. Food and Drug Administration scientists said the drugs appear to increase the risk of cancer after being used for more than 2 1/2 years. A yearlong study showed several dozen reports of cancer -- half of which...

2009-08-04 15:59:00

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab), Cimzia(R) (certolizumab pegol) and Simponi(R) (golimumab)]. This safety review was...

2009-07-31 09:40:00

EXTON, Pa., July 31 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the wave one LaunchTrends(TM): SIMPONI and CIMZIA report. The survey was completed by U.S. Rheumatologists in late June 2009. While awareness of both new TNF antagonists is relatively high, there are some troubling signs regarding initial impressions of these agents. The initial favorability rating for Simponi, for example, has slipped from 65% in the baseline report to 41% with the current wave of...

2009-07-20 07:00:00

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in Brazil will grow from $200 million in 2008 to more than $315 million in 2013. The 2008 market leaders were the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott's Humira and Schering-Plough's Remicade which recorded sales of $50 million and $43 million, respectively,...

2009-07-01 18:58:13

The risk of tuberculosis for patients who take arthritis drugs differs from that of the French population at large depending on the agent used, researchers say. Treatment with anti-tumor necrosis factor agents is recognized as a risk factor for TB in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Xavier Mariette of the Universite Paris-Sud says most TB cases develop as a result of...

2009-06-30 14:16:54

The U.S. District Court in Marshall, Texas, ordered Abbott Laboratories to pay Johnson & Johnson $1.7 billion in patent-related damages. Attorneys for Johnson & Johnson said Abbott's rheumatoid arthritis drug Humira, one of the top-selling drugs in the world, was made using technology developed exclusively for Johnson & Johnson at New York University. Humira earned more than $4 billion in sales in 2008. It differs from Johnson & Johnson's product Remicade, as it is fully...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related